Veefin Solutions Fund Raise of ₹35 Cr

Veefin Solutions Results Update

Veefin reported H1 FY27 revenue of ₹238.82 Cr (up 116% YoY) and PAT of ₹24.85 Cr. The company highlighted a ₹920 Cr opportunity pipeline in banking technology.

Veefin Solutions Investor Presentation: Key Takeaways

H1 FY27 group revenue ₹238.82 cr (+116.2% YoY), PAT ₹24.85 cr (+126.6%), EBITDA margin 25.5%. Standalone Q2 PAT flat; ₹920 cr pipeline, 84% outside India.

Veefin Solutions Q2 FY27 Results: Net Profit ₹15.3 Cr, Up 61.1% QoQ

Veefin Solutions Ltd reported revenue from operations of ₹124.7 Cr and net profit of ₹15.3 Cr for Q2 FY27.

Key figure

Net profit ₹15.3 Cr

Veefin Solutions Acquisition

Veefin Solutions disclosed its step-down subsidiaries' board-approved amalgamation, NTPL into WRM, via a Companies Act scheme. Consideration is share-based, with no cash paid.

Veefin Solutions Other Announcement

Veefin Solutions Ltd has filed its quarterly shareholding pattern as per SEBI Regulation 31. This is a routine regulatory compliance disclosure.

Veefin Solutions Board Meeting Date

Veefin Solutions has scheduled a Board meeting on October 26, 2026 to consider Q1 and H1 FY27 results. The trading window remains closed pending results declaration.

Rite Zone Chemcon India Fund Raise of ₹6.58 Cr

Rite Zone Chemcon India announced a preferential issue of 27,69,730 equity shares to 11 investors at Rs.24 each, raising about Rs.6.58 Crore. The approval awaits a shareholder vote on 23 November 2026.

Value

₹6.58 Cr

Sudarshan Pharma Industries Fund Raise of ₹72 Cr

Sudarshan Pharma's board approved up to Rs. 72 Crore of preferential convertible warrants for promoters Hemal and Sachin Mehta. Shareholder approval will be sought at an EGM.

Value

₹72.00 Cr

Flywings Simulator Training Centre Fund Raise of ₹68.2 Cr

Flywings Simulator's board approved Rs. 68.20 Crore fully convertible warrants on a preferential basis. Promoter Rupal Mandavia is allotted Rs. 25 Crore, subject to shareholder approval.

Value

₹68.20 Cr

Kanel Industries Fund Raise of ₹16.99 Cr

Kanel Industries' board approved a rights issue of 42.52 lakh equity shares at Rs.39.95 each. The issue aggregates about Rs.16.99 Crore, with record date 13 November 2026.

Value

₹16.99 Cr

Execution

Rights issue opens 23 November 2026 and closes 30 November 2026

Sudarshan Pharma Industries Fund Raise

Board approved issuing up to 72 Crore warrants to promoters on a preferential basis. Pricing per Reg 164 is pending, with no fixed rupee value stated.

GAIL (India) Fund Raise

GAIL Board approved in principle the IPO of subsidiary GAIL Gas Limited on Indian exchanges. GAIL will dilute its GGL equity up to 25%.